Fosun Pharma’s AR‑1001: How POLARIS‑AD Results Could Reshape Alzheimer’s Care
Shanghai Fosun Pharma’s POLARIS‑AD Phase III results reveal AR‑1001’s mixed efficacy, offering a promising oral Alzheimer’s therapy that could reshape pricing, reimbursement, and healthcare delivery for patients and payers.
- SHANGHAI FOSUN PHARMACEUTI-H
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
5 minutes to read










